Uso de metotrexato en pacientes con lupus eritematoso sistémico

Background: In the past ten years, methotrexate (MTX) has appeared as an alternative for the treatment of systemic lupus erythematosus (SLE). Aim: To evaluate the use of MTX and the results of treatment in a group of patients with SLE. Patients and Methods: Retrospective review of 426 files of patie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sánchez H,Yunchoy, Carvallo V,Aurelio
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2004
Materias:	Lupus erythematosus, systemic Methotrexate Prednisone
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000200009
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872004000200009
record_format	dspace
spelling	oai:scielo:S0034-988720040002000092005-11-23Uso de metotrexato en pacientes con lupus eritematoso sistémicoSánchez H,YunchoyCarvallo V,Aurelio Lupus erythematosus, systemic Methotrexate Prednisone Background: In the past ten years, methotrexate (MTX) has appeared as an alternative for the treatment of systemic lupus erythematosus (SLE). Aim: To evaluate the use of MTX and the results of treatment in a group of patients with SLE. Patients and Methods: Retrospective review of 426 files of patients with SLE. Of these, all patients treated with MTX were selected. A review protocol was designed, stating sex, age, time of disease evolution, previous treatment, MTX prescription, doses, effectiveness and side effects. Results: Seven patients were selected. All were women, with an age range of 26 to 62 years old and with 5 to 34 years of disease evolution. Previous treatment with non steroidal anti-inflammatory drugs, steroids, hydroxychloroquine and azathioprine ranged from 6 to 631 months (average=147.3). Persistent joint and/or skin manifestations were the main cause for the use of MTX. The dose ranged from 7.5 to 15 mg and the treatment lapse from 6 to 106 months. It was effective in all patients, allowing a reduction in prednisone doses. Two patients experienced a rise in serum transaminases and one had gastric intolerance, that required treatment discontinuation. Conclusions: MTX is rarely used in SLE. Its main prescription and effectiveness is in joint and skin manifestations, allowing to decrease steroid doses. However, side effects are frequent (Rev Méd Chile 2004; 132: 195-201)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.132 n.2 20042004-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000200009es10.4067/S0034-98872004000200009
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Lupus erythematosus, systemic Methotrexate Prednisone
spellingShingle	Lupus erythematosus, systemic Methotrexate Prednisone Sánchez H,Yunchoy Carvallo V,Aurelio Uso de metotrexato en pacientes con lupus eritematoso sistémico
description	Background: In the past ten years, methotrexate (MTX) has appeared as an alternative for the treatment of systemic lupus erythematosus (SLE). Aim: To evaluate the use of MTX and the results of treatment in a group of patients with SLE. Patients and Methods: Retrospective review of 426 files of patients with SLE. Of these, all patients treated with MTX were selected. A review protocol was designed, stating sex, age, time of disease evolution, previous treatment, MTX prescription, doses, effectiveness and side effects. Results: Seven patients were selected. All were women, with an age range of 26 to 62 years old and with 5 to 34 years of disease evolution. Previous treatment with non steroidal anti-inflammatory drugs, steroids, hydroxychloroquine and azathioprine ranged from 6 to 631 months (average=147.3). Persistent joint and/or skin manifestations were the main cause for the use of MTX. The dose ranged from 7.5 to 15 mg and the treatment lapse from 6 to 106 months. It was effective in all patients, allowing a reduction in prednisone doses. Two patients experienced a rise in serum transaminases and one had gastric intolerance, that required treatment discontinuation. Conclusions: MTX is rarely used in SLE. Its main prescription and effectiveness is in joint and skin manifestations, allowing to decrease steroid doses. However, side effects are frequent (Rev Méd Chile 2004; 132: 195-201)
author	Sánchez H,Yunchoy Carvallo V,Aurelio
author_facet	Sánchez H,Yunchoy Carvallo V,Aurelio
author_sort	Sánchez H,Yunchoy
title	Uso de metotrexato en pacientes con lupus eritematoso sistémico
title_short	Uso de metotrexato en pacientes con lupus eritematoso sistémico
title_full	Uso de metotrexato en pacientes con lupus eritematoso sistémico
title_fullStr	Uso de metotrexato en pacientes con lupus eritematoso sistémico
title_full_unstemmed	Uso de metotrexato en pacientes con lupus eritematoso sistémico
title_sort	uso de metotrexato en pacientes con lupus eritematoso sistémico
publisher	Sociedad Médica de Santiago
publishDate	2004
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872004000200009
work_keys_str_mv	AT sanchezhyunchoy usodemetotrexatoenpacientesconlupuseritematososistemico AT carvallovaurelio usodemetotrexatoenpacientesconlupuseritematososistemico
_version_	1718436135888224256

Uso de metotrexato en pacientes con lupus eritematoso sistémico

Ejemplares similares